影响采集异基因供者外周血干细胞的因素探讨

目的　探讨采集异基因供者外周血干细胞相关因素对干细胞得率的影响。方法　采用COBE -spectra血细胞分离机采集异基因外周血干细胞供者 2 1例 ,分析供者每次采集前后外周血WBC、有核细胞数 (NC)、单个核细胞比例 (MNC)等参数对干细胞采集得率的影响。选用不同剂量的G -CSF动员供者所采出CD3 4 + 细胞数量进行比较。结果　 2 1例供者的外周血均值变化为WBC( 4 1± 7 7)× 10 9/L ,MNC( 12± 2 9) % ,此时采集到的有核细胞数为 ( 2 7± 0 8)× 10 8/L ,而且得率较高。通过相关多元统计分析2 1例供者后得出NC对采集的单个核细胞得率之间存在直线正相关关系 (r =0 87,P <0 0 0 0 1)。结论　应用COBE -spectra血细胞分离机采集异基因供者外周血干细胞得率高 ,供者痛苦小 ,红细胞混杂率少、移植后成活率高。该方法目前仍是一种较为安全、快捷采集外周血干细胞的方法。     

骨髓非清除性造血干细胞移植后供者干细胞输注治疗非肿瘤性血液病的探讨

目的探讨非清髓性移植(NST)治疗移植排斥高风险的非肿瘤性血液病的植入效果、并发症。方法对2例重型再障(SAA)和1例重型β-地中海贫血(TM)患者实施NST。2例SAA患者采用G-CSF动员的骨髓联合外周血移植,预处理方案:抗淋巴细胞球蛋白联合减低剂量的环磷酰胺;TM患者实施外周血干细胞移植,预处理方案:抗胸腺细胞球蛋白、氟达拉滨联合减低剂量的马利兰。移植物抗宿主病(GVHD)预防:环孢素A联合甲基强的松龙;于+78d、+99d和+44d行供者干细胞输注(DSI)。结果移植后均形成混合性嵌合体,3例白细胞最低值:0.26×109/L、0.50×109/L、1.26×109/L;中性粒细胞绝对值>0.5×109/L和P lt>20×109/L的时间分别为+12d、+3d、0d和+1d、+5d、0d;3例经过DSI,造血和嵌合体有改善。均无感染、GVHD发生。结论NST后行DSI治疗排斥高风险非肿瘤性血液病,可以获得造血干细胞成功植入,减少并发症。     

同胞脐血移植治疗重型β-地中海贫血的临床研究

【目的】　探讨同胞脐血移植治疗重型 β 地中海贫血 (以下简称地贫 )的疗效。 　【方法】　用HLA全相合或不全相合同胞脐血移植治疗重型 β 地中海贫血患儿 7例。供给受者的有核细胞 ( 4 .5 5～ 16.0 )× 10 7/kg ,CD3 4 + 细胞 ( 0 .11～ 1.0 3 )× 10 6/kg ,粒 巨噬细胞集落形成单位 ( 0 .3 1～ 1.18)× 10 5/kg。移植的预处理方案HLA全相合的患儿采用马利兰 +环磷酰胺 +抗胸腺细胞球蛋白方案 ;HLA 2个位点不全相合者采用高剂量输血 +连续静注去铁胺 +羟基脲 +氟哒拉膑 +马利兰 +环磷酰胺 +抗胸腺细胞球蛋白方案。　【结果】　 7例患儿均获得植入 ,其中 6例患儿为长期稳定植入 ,1例植入后发生排斥。 7例患儿均发生急性移植物抗宿主病 ,其中Ⅰ度 5例 ,Ⅱ度 2例。脱离地贫状态生存 6例 ,血红蛋白一直维持正常 ,1例恢复地贫状态。　【结论】　同胞脐血移植可根治本病。     

苯中毒患者胸腺近期输出功能和T细胞亚群变化

目的　分析职业性慢性轻度苯中毒工人外周血单个核细胞中信号结合T细胞受体删除DNA环 (sjTRECs)的含量和CD4+/CD8+比值 ,从而了解其初始 (naive)T细胞含量和胸腺近期输功能 ,以及外周T细胞亚群分布情况。方法　利用间接免疫荧光法检测 11例健康人和 5例轻度苯中毒患者外周血单个核细胞中CD4+/CD8+比值 ;采用实时荧光定量聚合酶链反应 (real timePCR)和TaqMan方法检测两组外周血单个核细胞中sjTRECs的含量。结果　每 10 0 0个外周血单个核细胞中sjTRECs含量在正常人中为 9 10± 4 5 5 ,轻度苯中毒为 2 80± 3 79,P <0 0 5 ;轻度苯中毒者CD4+/CD8+的比值 (0 92± 0 3 5 )明显低于正常人 (1 49± 0 2 1) ,P <0 0 1。结论　轻度苯中毒患者胸腺近期输出功能低下 ,长期低剂量接触苯可能引起一些工人的细胞免疫功能障碍     

慢性湿疹589例斑贴试验结果分析

为分析职业性苯中毒工人外周血单个核细胞中T细胞受体删除DNA环(TRECs)的含量,了解苯中毒工人胸腺近期输出功能变化,采用实时荧光定量聚合酶链反应(real time PCR)和TaqMan方法检测苯中毒和健康人外周血单个核细胞中TRECs的含量。结果显示,TRECs含量苯中毒观察对象2·97±1·31、轻度苯中毒1·73±1·11、中度苯中毒2·28±1·44、重度苯中毒1·91±1·95,各组患者每1000个外周血单个核细胞中TRECs含量均明显低于健康组7·39±6·83(P<0·05),轻度和重度苯中毒组TRECs含量显著低于苯中毒观察对象组(P<0·05)。重度苯中毒组接苯时间>3的工人TRECs含量显著低于接苯时间≤3年者,苯中毒观察对象组接苯时间>5年的工人TRECs含量显著低于≤5年者(P<0·05)。提示苯中毒患者胸腺近期输出功能低下。     

异基因外周血造血干细胞移植治疗白血病

探讨用 Ｈ Ｌ Ａ 相合的同胞异基因外周血干细胞移植治疗急性髓细胞白血病及 Ａ Ｂ Ｏ 血型不合的 Ｐ Ｂ Ｓ Ｃ Ｔ 的情况,采用 Ｃ Ｔ Ｘ６０ｍｇ／ｋｇ ×２ ＋ Ｔ Ｂ Ｉ７０ ～７５ Ｇｙ 直线加速器照射＋ Ｃ Ｃ Ｎ Ｕ５０ｍｇ／ｋｇ ×１ ± Ｖ Ｐ１６３０ｍｇ／ｋｇ ×１ 对受者作预处理,供者经 Ｇ－ Ｃ Ｓ Ｆ６μｇ／ｋｇ ×５ｄ 动员后,用血细胞分离机（ Ｂａｘｔｅｒ Ｃ Ｓ３０００ｐｌｕｓ） 分离采集干细胞去除红细胞。对 Ａ Ｂ Ｏ 血型不合的 Ｐ Ｂ Ｓ Ｃ,强化移植物抗宿主病（ Ｇ Ｖ Ｈ Ｄ） 预防方案中 Ｍ Ｔ Ｘ 用量及次数;选输合适血制品。结果３ 例病人输注单个核细胞数分别为４０ 、１００ 、５０ ×１０８／ｋｇ , Ｃ Ｄ３４ ＋ 细胞分别为３６ 、１９０ 、２０ ×１０６／ｋｇ ;干细胞悬液中红细胞残存量分别为２３ｍｌ、１４ｍｌ、２６ ｍｌ,红细胞残存率分别为４ ％ 、３ ％ 、５３ ％ 。移植后造血重建迅速。例１ 于＋ ３４ｄ 染色体完全转变为供者型;例２ 于＋ ４０ｄ 血型完全转变为供者型,＋ ４５ｄ 染色体完全转变为供者型,例３ ＋ ５５ｄ 血型完全转变为供者型。没有输血溶血和免疫溶血发生。例２ 为主,次要 Ａ Ｂ Ｏ 均不合,则早期     

双份非血缘脐血移植治疗成人慢性苯中毒性白血病的疗效观察

目的 探讨双份非血缘关系脐血移植(UCBT)治疗成人慢性苯中毒性白血病的有效性及可行性.方法 对4例成人慢性苯中毒性白血病患者[急性非淋巴细胞白血病(ANLL-M2)2例、慢性粒细胞白血病(CML)-慢性期1例、CML-急变期1例]进行双份UCBT,其中人类组织相容性抗原(HLA)配型全相合1例,516位点相合2例,4/6位点相合1例.输入的单个核细胞数(MNC)为5.5×107～6.8×107/kg,CD34+细胞数为2.6×105～4.8×105/kg.预处理方案:在经典的白消胺(BU)/环磷酰胺(CY)预处理方案基础上加用抗胸腺细胞球蛋白(ATG);应用环孢素A(CsA)、赛尼哌、霉酚酸酯(MMF)+短程氨甲蝶呤(MTX)预防移植物抗宿主病(GVHD);采用肝素联合丹参、低分子右旋糖酐预防肝静脉闭塞病(HVOD).结果 3例植入成功,患者中性粒细胞绝对数恢复至≥0.5×109/L的时间分别为移植后15、30、18 d,血小板数≥20×109/L的时间分别为移植后31、65、40 d;DNA短串联重复序列多态性(DNA-STR)分析显示,仅有1份脐血植入,另1份被排斥,未发生GVHD.至今3例患者分别长期无病存活达69、70和39个月,其中1例HLA配型4/6位点相合、CML-急变期患者于移植后42 d恢复自身造血.结论 双份UCBT治疗成人慢性苯中毒性白血病是可行有效的.     

重度苯中毒患者T细胞受体 Vβ亚家族TRECs的分析

目的 检测重度苯中毒患者外周血23个TCR Vβ-Dβ1TRECs的存在情况,进一步了解重度苯中毒患者胸腺近期各Vβ亚家族初始T细胞的输出情况.方法 分别在5×104和1×104个外周血单个核细胞水平下,采用半巢式对12例重度苯中毒患者和10例正常人的23个TCRVβ-Dβ1TRECs进行扩增.结果 在5×104和1×104细胞水平下,苯中毒组检出各TCRVβ-Dβ1TRECs数均显著低于对照组(P＜0.05).在5×104细胞水平时,对照组检测到23个TCRVβ-Dβ1TRECs,苯中毒组仅检测到17个TCRVβ-Dβ1TRECs,其中12 个TCRVβ-Dβ1TRECs检出率与对照组相比明显降低(P＜0.05).结论 本研究提供了苯中毒患者外周血中各TCRVβ-Dβ1TRECs存在情况.苯中毒患者TCRVβ-Dβ1TRECs检出数量和检出率低于正常人,提示重度苯中毒患者胸腺近期输出功能存在部分缺陷和低下的情况.     

血液病患者医院感染与白细胞数关系的研究

目的　为了探讨恶性血液病患者医院感染与外周血白细胞数的关系及其感染病原学特点 ,为临床防治提供依据。方法　对我院 1996～ 2 0 0 0年共收治的 5 2 6例恶性血液病住院患者进行回顾性调查分析。结果　 5 2 6例恶性血液病患者 ,有 2 74例发生医院感染 ,感染率为 5 2 .0 9% ;白细胞数 <4 .0× 10 9/L组感染率 6 3.0 2 %、<1.0×10 9/L组感染率 95 .2 8%、≥ 4 .0× 10 9/L组感染率 16 .2 6 % ,与前两组比较 P<0 .0 0 1;白细胞数≤ 1.0× 10 9/L感染死亡率 4 6 .5 3%、>1.0× 10 9/L 感染死亡率 8.0 9% ,两组间比较 P<0 .0 0 1;感染的病原菌主要是铜绿假单胞菌、大肠埃希菌及肺炎克雷伯菌 ,其次为真菌。结论　白细胞减少是恶性血液病患者医院感染的主要危险因素 ,对白细胞数 <1.0× 10 9/L 的患者应加强护理 ,对病原菌应根据敏感药物合理使用抗生素 ,慎用广谱抗生素 ,以防真菌感染。     

实验性苯中毒引起罕见的骨髓粒细胞增多症

苯中毒文献报告极多 ,多为临床报道 ,绝大部分述及粒细胞减少或再生障碍性贫血 ,偶见白血病 ,实验研究结果与此相似。我们在苯中毒实验中发现 1例细胞增多症 ,现报告如下。ＳＤ大鼠在静式染毒柜内吸入染毒 ,浓度为 10 0 0ｍｇ/ｍ3 ,每天吸入时间 4ｈ ,共染毒 30ｄ。常规周围血测定结果 :13/2 0大鼠有粒细胞减少 ,骨髓内粒细胞增生抑制者为7/2 0 (与正常对照比较 ,周围血与骨髓片均有明显差异 ) ;另1例其周围血粒细胞明显增高 ,达 11.5× 10 9/Ｌ～ 16 .8×10 9/Ｌ(连续检查 3次 ) ,形态观察以环形分叶核和环形核为主 (均为成熟粒系 ) ,占白…     

Granulocyte-macrophage progenitor cells in allogenic bone marrow transplantation: correlation of progenitor cell content and regeneration in the graft

The amount of granuloid macrophage progenitors (CFU-GM) was studied in 16 donor bone marrows used for allogenic bone marrow transplantation in the National Institute of Haematology and Blood Transfusion between January, 1984 and January, 1988. In 10 bone marrow transplanted patients long-term follow up of bone marrow CFU-GM regeneration was carried out. Graft sizes were the following: 2.91 +/- 0.62 X 10(8)/kg body weight nucleated cells and 19.2 +/- 14 X 10(4)/kg body weight (CFU-GM. Preinfusion procedures (centrifugation and resuspension) did not alter CFU-GM content of the grafts. Separation of nucleated cells with hydroxyethylstarch, applied for ABO mismatched donor bone marrow, however, resulted in a 30 per cent loss in CFU-GM. Since higher than threshold graft-sizes for successful engraftment were used, no linear correlation between graft size and speed of granulocyte and platelet recovery was found. Significant difference between regeneration kinetics of bone marrow CFU-GM of patients transplanted for CML or AML and ALL was observed: in AML and ALL patients normal bone marrow CFU-GM level was found 4 to 6 months after transplantation, while in CML patients CFU-GM level approached the lower limit of the normal value only 10 to 14 months after transplantation. Granulocyte and thrombocyte recovery of CML patients showed a significant delay when compared to transplanted AML and ALL patients.     

FC预处理方案异基因外周血干细胞移植治疗重型再生障碍性贫血

目的探索氟达拉滨（Flu）＋环磷酰胺（CTX）预处理方案（Fc预处理方案）异基因造血干细胞移植治疗重型再障的可行性。方法9例重型再障患者接受HLA全相合并基因造血干细胞移植。预处理方案采用FC方案：即氟达拉滨（Flu）30mg／m^2，静脉滴注，1／d，d-6-d-2，共5d；环磷酰胺（CTX）50mg／kg，静脉滴注，1／d，d-5-d-2，共4d。环孢素A（CsA）＋骁悉（MMF）联舍方案预防移植物抗宿主病（GVHD）。结果9例患者均成功植入，中性粒细胞≥0．5×10^9／L的时间中位时间为12（10-16）d，PLT≥20×10^9／L的时间中位时间为14（12-19）d。移植后30d检测证实均为供者型完全嵌合状态。1例发生肠道Ⅱ度急性GVHD，1例发生皮肤I度急性GVHD，1例出现慢性GVHD，Ⅱ度以上（含Ⅱ度）急性GVHD总发生率仅为11．1％。中位随访时间39个月，9例患者均无病存活。结论Fc预处理方案植入率高，预处理相关并发症少，无病生存率高，临床疗效好。     

Cord blood transplantation for adult patients with hematological malignancies

BACKGROUND: Recently, clinical studies of cord blood transplantation (CBT) in adults after myeloablative or nonmyeloablative conditioning regimens showed cord blood (CB) could effectively restore hematopoiesis and was associated with acceptable levels of graft versus host disease (GVHD). METHODS: This study reports the results of cord blood transplantation in 7 adults with hematological malignancies. RESULTS: Median age was 56 years (range, 43-69 years). HLA match was 4 of 6 in 4 cases and 5 of 6 in 3 cases. Median nucleated cell dose was 2.74 x 10(7) cells/kg (range, 2.13-3.80) and CD34+ cell dose was 1.15 x 10(5) cells/kg (range, 0.44-2.79). Three patients had primary graft failure. There was one early death at day 24 after CBT due to pneumonia. Three patients with engraftment are alive and free of disease at day 390, day 348 and day 164 after CBT. Acute GVHD grade II occurred in 2 cases with engraftment, and chronic GVHD occurred in 1 of 3 evaluable patients. Six patients with and without engraftment received more than 2.0 x 10(7) cells/kg nucleated cells. Three patients without engraftment received CD34+ cell dose less than that of 3 patients with engraftment. CONCLUSIONS: It is considered that graft CD34+ cell dose besides nucleated cell dose is important for engraftment. We believe that adult patients without suitable related or unrelated bone marrow donors should be considered as candidates for CBT by the choice of CB including both sufficient nucleated cell dose and CD34+ cell dose.     

Hematopoietic stem-cell transplantation in aplastic anemia

Severe aplastic anemia is a rare syndrome characterized by bone marrow failure with cytopenias and hypocellular bone marrow biopsy (usually 10-15%), without blasts or myelodysplasia. The first choice treatment for these patients is allogeneic bone marrow transplantation from a sibling matched for HLA-A, HLA-B and HLA-DR. Unfortunately only 30% of patients have an HLA-matched sibling (a 25% chance per sibling). The alternative treatment for severe aplastic anemia for the rest of the patients (70%) is immunosuppression with antithymocyte globuline and cyclosporine. The evolution of bone marrow transplantation since 1970's has been positive in terms of survival and transplant success (initial overall survival 43% vs. 90% lately, and graft rejection of 29% vs. 4%). The favorable outcome of bone marrow transplantation for severe or very severe aplastic anemia is due to: the use of conditioning with antithymocyte globuline and cyclophosphamide, the use of graft-vs.-host disease prophylaxis with short curse methotrexate and cyclosporine and the use of filtrated and irradiated blood products. For those patients without an HLA-matched related donor the first treatment to use is the immunosuppression with antithymocyte globuline and cyclosporine. Another option emerged in the late 80's is the unrelated bone marrow transplantation, with survival hardly half of the HLA-identical related bone marrow transplants. In our country, the first allogeneic bone marrow transplant was done in the Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, in a patient with aplastic anemia, making possible to perform this procedure safely in our country.     

异基因外周造血干细胞移植与免疫抑制治疗重型再生障碍性贫血的临床比较

目的 比较异基因外周造血干细胞移植(Allo-PBSCT)与免疫抑制治疗(IST)重型再生障碍性贫血(SAA)的疗效与并发症.方法 25例SAA患者接受了两种方法治疗:PBSCT组12例接受了同胞HLA全相合的PBSCT,预处理方案为:环磷酰胺(Cy)联合兔抗人胸腺免疫球蛋白(ATG);IST组13例治疗方案为:ATG/环孢素A(CsA).比较两种治疗方法的近期疗效、远期疗效与并发症.结果 PBSCT组的中性粒细胞计数、Pt和Hb的恢复时间[分别为(13.5±2.3)、(23.5±4.1)、(82.7±6.1)d]快于IST组[分别为(32.6±3.5)、(73.8±6.2)、(296.4±12.5)d](P<0.05),但1年的近期疗效比较差异无统计学意义(P>0.05).两组3年生存率和总生存率比较差异均无统计学意义(P>0.05),总复发率比较差异有统计学意义(P<0.05).结论 Allo-PBSCT和IST都是治疗SAA的有效手段,但Allo-PBSCT具有造血重建快、复发率低、并发症并没有增加等特点,临床上可作为优先选择.     

Allogenic hematopoietic stem cell transplantation in acquired aplastic anemia: first experience of the National Center for Bone Marrow Grafting

Bone marrow transplantation from HLA-identical sibling offers cure and leads to restoration of normal hematopoiesis and long-term survival in 60-80% of recipients. From february 1998 to october 1999, seven patients with aplastic anemia (2 very severe aplastic anemia and 5 severe aplastic anemia), with a median age of 22 years (14-39), received a transplant from an HLA-identical sibling donor. All patients had sustained engraftment. Only one patient developed grade IV acute graft-versus-host disease. One patient died in the 22th day of systemic mycobacterial infection and one in the 79th day of acute graft-versus-host disease. The remaining 5 patients are alive and have a complete hematological recovery, with a median follow-up of 6 months (1,5-12). There are at least two reasons for the improved survival of patients with aplastic anemia who where treated by HLA-indentical bone marrow transplantation. One is the decreased incidence of graft rejection that has resulted from the more judicious use of transfusions before bone marrow transplantation, and improvements in the immunosuppressive qualities of the conditioning programs. Another reason for improved survival is the decrease in the incidence and severity of acute graft-versus-host disease.     

Outpatient management of patients infected with human immunodeficiency virus.

The outpatient management of patients infected with human immunodeficiency syndrome is reviewed. Patients with CD4+ cell counts of greater than 0.5 x 10(9)/L (500/mm3) require no specific intervention except vaccination against influenza, pneumococcus, and possibly hepatitis B. They should have a follow-up examination every 3 to 6 months. Because of its success in preventing the progression of the disease, zidovudine (AZT), 100 mg five times per day, is recommended for patients with CD4+ cell counts of less than 0.5 x 10(9)/L (500/mm3). During this stage of the disease, a patient should be seen every 1 to 3 months and monitored for drug toxicity and disease progression. Patients with CD4+ counts of less than 0.2 x 10(9)/L (200/mm3) are at high risk of developing Pneumocystis carinii pneumonia. Prophylaxis with oral trimethoprim-sulfamethoxazole (one double-strength tablet three times weekly) or dapsone (100 mg three times weekly) is recommended. Treatment costs for the patient with CD4+ cells less than 0.5 x 10(9)/L (500/mm3) are at least $3000 per year.     

A single-institution, 20-year prospective experience with an affordable Fc-receptor blockade method to treat patients with chronic, refractory autoimmune thrombocytopenic purpura

In a 20-year period in a single institution, 34 patients with chronic, refractory autoimmune thrombocytopenic purpura were prospectively treated with ex vivo anti-D opsonized autologous red blood cells. All patients had received previous treatment with steroids and/or immunosuppressive agents, and 11 had been splenectomized. Twenty one patients had an increase in the platelet count; in five cases, the increase was more than 50 x 10(9)/L platelets and in 16 the increase was more than 100 x 10(9)/L platelets. Early responses were observed in 20 patients and late responses in seven, whereas seven patients (20%) did not respond at all. Nine of the 20 individuals who achieved an ER had a subsequent drop in the platelet count; however, only three had a drop below 50 x 10(9)/L. When last censored, of the 34 patients, 24 (70%) had a platelet count above 50 x 10(9)/L. The 84-month thrombocytopenia-free (over 50 x 10(9)/L platelets) status of the whole group is 70%, whereas the 84-month complete remission (over 100 x 10(9)/L platelets) status of the whole group is 50%. It is concluded that the use of ex vivo anti-D opsonized red blood cells may represent another, substantially cheaper treatment of patients with chronic, refractory, autoimmune thrombocytopenic purpura.     

Comparison of the efficacy of medium chain triglycerides with long chain triglycerides in total parenteral nutrition in patients with hematologic malignancies undergoing peripheral blood stem cell transplantation

BACKGROUND AND AIMS: The purpose of this randomized study was to compare the efficacy of medium chain triglycerides (MCT) plus long chain triglycerides (LCT) with LCT alone in total parenteral nutrition (TPN) solutions in patients with various hematologic malignancies who underwent a hematopoietic peripheral blood stem cell (PBSC) transplantation. METHODS: Of 36 patients entering into this study, 18 received MCT + LCT (group I) and the remaining 18 received LCT alone (group II) in TPN solutions. Patients were comparable regarding age, gender, donor-recipient gender, diagnosis, body weights, blood group differences and number of infused CD34(+) cells/kg. Post - transplant parameters such as duration of platelet and neutrophil engraftment, coagulation parameters, number of days of febrile neutropenia and antibiotic administration, plasma glucose, triglyceride, cholesterol and albumin levels, graft-versus-host disease (GVHD) and first 100 day mortality were compared in both groups. RESULTS: Median days of neutrophil >0.5 x 10(9)/l and platelet of >20 x 10(9)/l in group I and group II were 15 (range, 8-21), 11 (10-29) and 14 (range, 9-31), 13 (9-18) respectively (P>0.05). Median days of febrile neutropenia in group I and II were 10 (range, 4-23) and 7 (2-13) respectively (P=0.01). Median days of antibiotic administration in group I and II were 12 (range, 6-22) and 8 (4-25) respectively (P=0.04). Pre, peri- and post-transplant coagulation parameters such as PT, aPTT, and fibrinogen did not differ significantly between two groups (P>0.05), as well as plasma glucose, triglyceride, cholesterol, albumin levels, GVHD and first 100 day mortality. CONCLUSION: There was no difference between patients receiving MCT + LCT (group I) and LCT alone (group II) in TPN solutions regarding duration of engraftment and coagulation parameters, but numbers of median days of febrile neutropenia and days of antibiotic administration were significantly shorter in patients receiving LCT alone (group II) than those receiving MCT + LCT (P<0.01 and 0.04 respectively).     

Prevention of garlic-induced hemolytic anemia using some tropical green leafy vegetables

Garlic (Allium sativum) is popularly consumed in Nigeria because of its health benefit in treatment and management of several disease conditions. However, excessive intake of garlic may cause hemolytic anemia. This project sought to investigate the ability of some commonly consumed tropical green leafy vegetables-namely, Amaranthus cruentus, Baselia alba, Solanum macrocarpon, Ocimum gratissimum, and Corchorus olitorius-to prevent garlic-induced hemolytic anemia. Wister strain albino rats were fed diet containing 4% garlic with or without 40% vegetable supplement. The study showed that there was a decrease in daily feed intake (6.7-7.2 g/rat/day), daily weight gain (0.7-1.5 g/rat/day), and digestibility (70.4-91.5%) of rats fed diet with garlic (4%), with or without vegetable (40%) supplement, compared with those rats fed the basal diet without garlic (4%) and vegetable (40%) supplement (digestibility, 95.5%; daily feed intake, 7.5 g/rat/day; and daily weight gain, 2.0 g/rat/day). However, there was a significant decrease (P < .05) in the packed cell volume (PCV) (31.0%), hemoglobin (Hb) (10.2 g/dL), red blood cells (RBCs) (4.3 x 10(6)/microL), and white blood cells (WBCs) (3.5 x 10(6)/microL) of rats fed diet with garlic (4%) but without vegetable compared with those rats fed diet without garlic (4%) and vegetable (40%) supplements (PCV, 38.2%; Hb, 13.0 g/dL; RBCs, 5.5 x 10(6)/microL; and WBCs, 4.0 x 10(6)/microL). Conversely, there was a significant increase in the PCV (33.5-35.6%), Hb (12.0-12.5 g/dL), and RBCs (4.9-5.3 x 10(6)/microL) of rats fed diet with garlic (4%) and vegetable (40%) supplement compared with rats fed diet with 4% garlic supplement (except S. macrocarpon and C. olitorius). Furthermore, there was a significant decrease (P < .05) in mean corpuscular volume (69.2-72.0 fL) of rats fed the basal and those fed diet with garlic and vegetable (except C. olitorus and S. macrocarpon) supplement compared with the rats fed diet with garlic but without vegetable supplement (74.5 fL). This therefore implies that garlic could induce hemolytic anemia in rats. However, such anemia could be prevented by some tropical green leafy vegetables such as A. cruentus, B. alba, and O. gratissimum.